Currently, most plasma types must match a patient’s blood-type to prevent incompatibilities and reduce the risk of major transfusion reactions. Only type AB plasma, which lacks blood type-specific antibodies, can be used in transfusions for any patient regardless of blood type.
Since there are not enough type AB plasma donors to meet the current demand, CytoSorbents plans to adapt its HomoDefend technology to remove blood type-specific antibodies from all types of plasma, creating the possibility of universal plasma.
This U.S. Army Medical Research Acquisition Activity is funding the project.
If the company’s phase I efforts prove successful, CytoSorbents will be eligible to earn phase II funding, totaling over $1 million.
More articles on supply chain:
Cerus closes deal with BARDA to fund pathogen reduction technology for up to $180M
Why this cancer drug is being fast-tracked for FDA approval
Medtronic’s new surgical device earns FDA clearance for use in epilepsy clinical trial
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
